Vimta Labs Limited (VIMTALABS)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹572.75 ↑ 23.5% (1Y)

🎯 Key Takeaways

Vimta Labs Limited is in a growth phase, driven by consistent top-line expansion and improving operational margins, particularly in Q1 FY27 where operating profit margin reached 36.8%.
Revenue grew 6.1% QoQ to ₹90 in Q3FY25.
⚠️ Margin sustainability: While OPM improved to 36.8% in Q3 FY25, it remains subject to operational leverage and cost control in healthcare service deliv

Market Cap

₹2,012

P/E Ratio

32.8

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About VIMTALABS 📊 Interactive Charts

📖 The Story

Vimta Labs Limited is in a growth phase, driven by consistent top-line expansion and improving operational margins, particularly in Q1 FY27 where operating profit margin reached 36.8%. The company maintains a stable leadership structure with Dr Sujani Vasireddi reappointed as Executive Chairman and a history of promoter unencumbrance, supporting governance continuity. Recent financial performance reflects accelerating revenue growth and margin expansion, aligning with strategic investments in healthcare services infrastructure.

📰 What's Happening

In Q1 FY27, Vimta Labs reported revenue of ₹90 crore with operating profit of ₹34 crore, up from ₹85 crore revenue and ₹31 crore operating profit in Q2 FY25. The company scheduled an investor conference call on July 20, 2026, to discuss these unaudited results. At the 36th AGM on June 25, 2026, shareholders approved the audited FY2025-26 financials and declared a dividend of Rs2 per share. Additionally, on June 2, 2026, the company confirmed promoter shareholdings remained unencumbered under SEBI takeover norms, reinforcing governance stability.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	82	83	73	82	80	82	85	90
Operating Profit	25	25	18	23	25	25	31	34
OPM %	29.6%	29.5%	21.6%	26.7%	30.6%	30.0%	35.3%	36.8%
Net Profit	13	12	6	10	12	12	15	22
EPS	₹5.73	₹5.51	₹2.85	₹4.57	₹5.58	₹5.54	₹6.88	₹9.65

Revenue has grown steadily from ₹73 crore in Q2 FY24 to ₹90 crore in Q3 FY25, with operating margins expanding from 21.6% to 36.8% over the same period. This improvement follows a prior dip in margins during FY24, suggesting operational efficiencies or scale benefits are now materializing. Net profit rose from ₹6 crore in Q2 FY24 to ₹22 crore in Q3 FY25, indicating stronger profitability despite macroeconomic headwinds. The margin trajectory aligns with management's focus on high-margin service lines and operational scaling.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the disclosed filings, but the scheduling of an investor call to discuss Q1 FY27 results suggests upcoming commentary on performance trends. The reappointment of Dr Sujani Vasireddi as Executive Chairman and ratification of auditor remuneration at the AGM signal confidence in governance and financial oversight. No formal revenue or margin targets were disclosed, but the focus on compliance and stakeholder communication reflects a disciplined, transparent approach.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1. Margin sustainability: While OPM improved to 36.8% in Q3 FY25, it remains subject to operational leverage and cost control in healthcare service delivery. 2. Market competition: The healthcare services sector faces pricing pressure from organized players, which could challenge revenue growth if not differentiated. 3. Regulatory exposure: Compliance with SEBI takeover norms and healthcare regulations requires ongoing vigilance, though currently no encumbrances exist. 4. Dividend sustainability: Declaring Rs2 per share dividend amid rising operational costs may pressure liquidity if profitability fluctuates.

📋 Recent Filings

🧠 Analyst's Read

Vimta Labs is demonstrating consistent financial improvement with expanding margins and revenue growth, supported by stable governance and promoter transparency. Investors should monitor the upcoming investor call for insights into FY27 outlook and any commentary on margin trajectory or market strategy. The key watchpoints are operational scalability and whether recent margin gains are structural or cyclical.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIMTALABS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when VIMTALABS files new disclosures

Track VIMTALABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIMTALABS — Free

Free account · 2 AI queries/day